|Printable version||E-mail this to a friend|
Markets in financial instruments: Negotiations to start on one-year delay
On 28 April 2016, the Permanent Representatives Committee (Coreper) agreed, on behalf of the Council, its negotiating stance aimed at extending by one year the dates of transposition and application of new securities market rules.
The one-year extension will affect the provision of services for investments in financial instruments and on the operation of regulated financial markets. Coreper asked the Netherlands presidency to start negotiations with the European Parliament as soon as possible, so as to enable adoption at first reading of a regulation enacting the extension.
"MIFID" and "MIFIR"
A recent revision of rules on financial instruments set out to promote the integration, competitiveness, and efficiency of EU financial markets. The Council adopted these in May 2014, amending and replacing an existing "MIFID" text that regulates markets in financial instruments.
The rules consist of two legislative instruments:
- regulation 600/2014 ("MIFIR"), aimed at improving transparency and competition of trading activities by limiting the use of waivers on disclosure requirements and by providing for non-discriminatory access to trading venues and central counterparties (CCPs) for all financial instruments, and requiring derivatives to be traded on organised venues;
- directive 2014/65/EU ("MIFID II"), amending rules on the authorisation and organisational requirements for providers of investment services and on investor protection. The directive also introduces a new type of trading venue, the organised trading facility (OTF). Standardised derivatives contracts are increasingly traded on these platforms, which are currently not regulated.
Under the Council's approach:
- the deadline for the member states to transpose MIFID II into national legislation would be set for 3 July 2017;
- the date of application of both MIFID II and MIFIR would be set for 3 January 2018.
Additionally, the Council included amendments to the Commission's proposal in its negotiating mandate. These concern trading on own accounts, package transactions, alignment with the EU directive on securities financing transactions and the date of application of certain provisions of a regulation on market abuse.
Both the directive and the regulation were to become applicable 30 months after entry into force, i.e. as of 3 January 2017, with member states having to transpose the new directive by 3 July 2016. However, due to technical implementing challenges faced by the European Securities and Markets Authority (ESMA) and by national competent authorities, essential data infrastructures will not be in place by 3 January 2017.
The new framework requires trading venues and systematic internalisers to provide competent authorities with financial instrument reference data that describes in a uniform manner the characteristics of every financial instrument subject to the scope of MiFID II. In order to collect data in an efficient and harmonised manner, a new data collection infrastructuremust be developed. This obliges ESMA, in conjunction with competent national authorities, to establish a data system covering a wider range of financial instruments, given the extended scope of MiFID II.
On 2 October 2015, ESMA informed the Commission that a delay in the technical implementation of MiFID II was unavoidable. Neither competent authorities nor market participants will be in a position to apply the new rules on 3 January 2017. This would lead to legal uncertainty and potential market disruption.
 By setting an overall EU cap and a cap per trading venue for the so-called reference price waiver and negotiated transaction waiver.
- Draft directive amending MIFID II as regards certain dates
- Draft regulation amending MIFIR and two other regulations as regards certain dates
- Council press release on new rules on markets in financial instruments
Latest News from
Multilateral banks to deepen collaboration with private sector to boost inclusive, sustainable infrastructure24/04/2017 16:20:00
Leaders of the top multilateral development banks (MDBs) have agreed to deepen their collaboration to encourage private sector investment in vital infrastructure needed to support sustainable and inclusive economic growth throughout the world.
Revised guidelines to encourage development of veterinary medicines for minor uses & minor species24/04/2017 15:05:00
Guidelines clarify data needed for authorisation of medicines for treatment of minor-use-minor-species/ limited-market
First medicine for spinal muscular atrophy24/04/2017 14:20:00
Orphan medicine Spinraza recommended by CHMP under accelerated assessment
New medicine for rare neurodegenerative disorder in children24/04/2017 13:10:00
The European Medicines Agency (EMA) has recommended granting a marketing authorisation in the EU for Brineura (cerliponase alfa) for the treatment of a very rare, fatal neurodegenerative condition in children called neuronal ceroid lipofuscinosis type 2 (CLN2) disease.